Prof. Pruneri is a full professor in pathology at the University of Milan School of Medicine, and is Chair of the Department of Pathology and Laboratory Medicine with the National Cancer Institute of Milan, a comprehensive cancer centre fully equipped for translational research and innovative care, including a molecular lab for next-generation sequencing. He is devoted to translational research programs, currently focused in breast pathology, sustained by several national and international peer-reviewed grants, resulting in more than 280 publications yielding to a H-index of 55. He is involved in several international networks, including the International Breast Cancer Study Group (IBCSG), in which he was appointed as chair of the Translational Research Working Group and in the International Immuno-Oncology Working Group, which is focused on the validation of biomarkers for immunotherapy.
SCIENTIFIC ADVISORY BOARD
Experienced and Innovative Technologies
Dr. Hirano is currently the Scientific Director at SENTAN Pharma Inc. (Major; Nanoparticle), Japan. He has a distinguished career in Cell Engineering, with several senior positions at National Institute of Advanced Industrial Science and Technology (AIST), Ministry of Engineering, Trade and Industry (METI), Japan. He also served as the CTO at Okinawa Institute of Advanced Sciences and Program Director, OKINAWA Intellectual Cluster Project. Including genome sequencing, regenerative medicine, as well as infectious diseases. Dr. Hirano received his bachelor’s degree in Engineering from Tokyo University, and Master and Ph.D. degrees from Graduate School of Tokyo University (Synthetic Polymer Chemistry). He received DAAD and Humboldt Fellowship for post-doctoral research at Mainz University, Institute of Macromolecular Chemistry, Germany (Polymeric Drug Delivery System). He was also a Visiting Fellow at National Cancer Institute, National Institutes of Health (NIH), USA (Cancer Chemotherapy). Dr. Hirano is a recipient of several awards including Innovation Award, Science and Technology Agency, Japan.
Prof. Rizzolio is a molecular biologist at Ca’ Foscari University of Venice in the Department of Molecular Sciences and Nanosystems and adjunct professor at Temple University in the Department of Biology. He lead different National and International research programs in the field of cancer biology and nano medicine publishing more than 100 of peer reviewed scientific articles. Interesting discoveries for market have been protected by patents. Prof. Rizzolio is the founder and CEO of Biofuture Medicine, a biotech company with a focus on cancer and is actively collaborating with different companies in the field of diagnostic medicine.
Dr. Cohen is the Senior Director for the Division of Cytogenetics and Molecular Pathology in the Department of Pathology at Northwell Labs (Northwell Health). Dr. Cohen has been a part of Northwell Labs leadership team since 2017, overseeing the clinical and academic activities of the genetics labs at North Shore University Hospital and Long Island Jewish Medical Center. Dr. Cohen has introduced automation and numerous quality improvement initiatives which have resulted in improved turnaround time of patient results as well as outstanding provider and employee satisfaction. Dr. Cohen is dual board certified in Clinical Cytogenetics and Clinical Molecular Genetics by the American Board of Medical Genetics and Genomics, is a Fellow of the American College of Medical Genetics and Genomics and holds a New York State Certificate of Qualification in Cytogenetics and Molecular Genetics. Dr. Cohen’s areas of interest include introducing innovative technology in the labs, medical education, quality improvement, lab communication and client relations.
Dr. Cohen received her Bachelor of Science degree in Biology from SUNY at Stony Brook, New York, Master of Science degree and a PhD degree in Human Genetics from Tel Aviv University, Sackler School of Medicine, Israel, and post-doctoral fellowships in Clinical Cytogenetics and Clinical Molecular Genetics from the American Board of Medical Genetics and Genomics (ABMGG) at the Icahn School of Medicine at Mount Sinai, NY.